Editorials Sulfonylureas as second line treatment for type 2 diabetes BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3041 (Published 18 July 2018) Cite this as: BMJ 2018;362:k3041 Article Related content Metrics Responses Peer review Related articles Research Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study Published: 18 July 2018; BMJ 362 doi:10.1136/bmj.k2693 ResearchSulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events See more FDA announces crackdown on e-cigarettes in bid to reduce teenage vaping BMJ November 20, 2018, 363 k4908; DOI: https://doi.org/10.1136/bmj.k4908 Monitoring glycaemic control in patients with diabetes mellitus BMJ November 20, 2018, 363 k4723; DOI: https://doi.org/10.1136/bmj.k4723 GMC checks 3000 doctors’ credentials after fraudulent psychiatrist practised for 23 years BMJ November 20, 2018, 363 k4909; DOI: https://doi.org/10.1136/bmj.k4909 Why we shouldn’t use the term “illegal migrant” BMJ November 20, 2018, 363 k4885; DOI: https://doi.org/10.1136/bmj.k4885 Austerity in the UK: rising poverty threatens stability and health BMJ November 20, 2018, 363 k4897; DOI: https://doi.org/10.1136/bmj.k4897
